David-Alexandre Gros
Förmögenhet: 13 M $ per 2026-07-31
Förmögenhet: 13 M $ per 2026-07-31
Dr. David-Alexandre C.
Gros is a Chief Executive Officer & Director at Eledon Pharmaceuticals, Inc. He is on the Board of Directors at Eledon Pharmaceuticals, Inc. Dr. Gros was previously employed as a Chairman & Chief Executive Officer by Sabeton SA, a Chairman & Chief Executive Officer by Imbria Pharmaceuticals, Inc., a President, Chief Operating & Financial Officer by Neurocrine Biosciences, Inc., a Chief Financial Officer by Alnylam Pharmaceuticals, Inc., a Member-Supervisory Board by Sabeton SA, a Chief Strategy Officer & Executive Vice President by Sanofi, a Chief Strategy Officer by Sanofi, a Principal by Centerview Partners LLC, and an Associate Principal by McKinsey & Co., Inc. He also served on the board at Eliem Therapeutics, Inc. He received his undergraduate degree from Dartmouth College, an MBA from Harvard Business School and a doctorate degree from The Johns Hopkins University School of Medicine.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
SAINT JEAN GROUPE SA 15,62 % | 2026-05-07 | 500 000 ( 15,62 % ) | 12 M $ | 2026-07-31 |
| 2026-07-31 | 168 663 ( 0,22 % ) | 570 081 $ | 2026-07-31 |
| Företag | Position | Start |
|---|---|---|
| ELEDON PHARMACEUTICALS, INC. | Verkställande Direktör | 2020-09-09 |
| Företag | Position | Slut |
|---|---|---|
| SAINT JEAN GROUPE | Verkställande Direktör | 2026-06-30 |
| CLIMB BIO, INC. | Grundare | 2020-10-01 |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Verkställande Direktör | 2020-09-01 |
| NEUROCRINE BIOSCIENCES, INC. | President | 2017-12-31 |
| ALNYLAM PHARMACEUTICALS, INC. | Finansdirektör/CFO | 2017-01-06 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 12 |
|---|---|
Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
Sanofi
Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
Dartmouth College
Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Saint Jean Groupe SA
Saint Jean Groupe SA Food: Major DiversifiedConsumer Non-Durables Operates as an investment holding company with the interest in agro foods sector | Consumer Non-Durables |
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutics based on RNA interference | Health Technology |
Centerview Partners LLC
Centerview Partners LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Johns Hopkins University School of Medicine
The Johns Hopkins University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals | Health Technology |
Imbria Pharmaceuticals, Inc.
Imbria Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a clinical stage company for the treatment of cardiovascular disease | Commercial Services |
Eliem Therapeutics, Inc.
Eliem Therapeutics, Inc. BiotechnologyHealth Technology Operates as clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån